Status:
UNKNOWN
Efficacy of Tazarotene in Treatment of Verruca Plana
Lead Sponsor:
Zagazig University
Conditions:
Warts Flat
Eligibility:
All Genders
4+ years
Phase:
PHASE2
Brief Summary
Verruca plana is a common skin infection with worldwide distribution. Approximately 10% of general population is infected with flat warts and it represents up to 18 % of the patients seeking treatment...
Detailed Description
Patients will be assigned randomly into one of 4 groups as 1:1:1:1 using randomization.com with the seed number 7607 * Group (A): Patients will be treated with topical tazarotene gel 0.1%with a cotto...
Eligibility Criteria
Inclusion
- All participants must be willing to sign informed consent; for patients younger than 18 years old, parents or guardians will sign an informed consent
- Age \> 4 years.
- Both sexes.
- Patients with clinically and dermoscopically diagnosed plane warts.
- Subject is willing and able to follow all study instructions and to attend all study visits
Exclusion
- • History of hypersensitivity to any of the drugs used.
- Pregnancy and lactation.
- Patients with epidermodysplasia verruciformis syndrome.
- Patients with eczematous skin disorders.
- Presence of any active infections e.g. herpes, tuberculosis.
- History of topical anti wart treatment within 4 weeks of recruitment to the study, and a 12-week period for systemic anti-wart treatment, or immunotherapy, or HPV vaccine in the last 24 weeks.
Key Trial Info
Start Date :
April 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05314127
Start Date
April 15 2022
End Date
December 1 2022
Last Update
May 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermatology department, Zagazig University Hospitals, Faculty of Medicine, Zagazig University
Zagazig, Select Region, Egypt, 44511